Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hansoh In-Licenses China Rights to Anti-CD19 mAb in $220 Million Deal

publication date: May 28, 2019

Jiangsu Hansoh Pharma will collaborate with Viela Bio of Gaithersburg, Maryland to develop and commercialize inebilizumab in China in a $220 million agreement that includes upfront and milestone payments, plus royalties. Inebilizumab, Viola's humanized anti-CD19 mAb, produced positive data in US pivotal trials for neuromyelitis optica spectrum disorder, a CNS autoimmune disease. Viela believes the candidate will also prove effective against other inflammation/autoimmune and hematologic malignancy indications. Last month, Hansoh filed for a Hong Kong IPO that is expected to raise between $500 million and $1 billion. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital